Ambu A/S

PINK:AMBFF USA Medical Devices
Market Cap
$4.62 Billion
Market Cap Rank
#3642 Global
#2364 in USA
Share Price
$19.90
Change (1 day)
+0.00%
52-Week Range
$19.90 - $19.90
All Time High
$55.36
About

Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as… Read more

Ambu A/S (AMBFF) - Net Assets

Latest net assets as of June 2025: $5.91 Billion USD

Based on the latest financial reports, Ambu A/S (AMBFF) has net assets worth $5.91 Billion USD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.40 Billion) and total liabilities ($1.49 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $5.91 Billion
% of Total Assets 79.84%
Annual Growth Rate 35.01%
5-Year Change 135.83%
10-Year Change 439.96%
Growth Volatility 800.79

Ambu A/S - Net Assets Trend (2000–2024)

This chart illustrates how Ambu A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Ambu A/S (2000–2024)

The table below shows the annual net assets of Ambu A/S from 2000 to 2024.

Year Net Assets Change
2024-09-30 $5.59 Billion +3.73%
2023-09-30 $5.39 Billion +26.57%
2022-09-30 $4.26 Billion +7.82%
2021-09-30 $3.95 Billion +66.61%
2020-09-30 $2.37 Billion +8.71%
2019-09-30 $2.18 Billion +15.94%
2018-09-30 $1.88 Billion +47.15%
2017-09-30 $1.28 Billion +28.93%
2016-09-30 $992.00 Million -4.25%
2015-09-30 $1.04 Billion +21.31%
2014-09-30 $854.00 Million +28.04%
2013-09-30 $667.00 Million -1.64%
2012-09-30 $678.11 Million +16.94%
2011-09-30 $579.86 Million +3.25%
2010-09-30 $561.60 Million +17.09%
2009-09-30 $479.62 Million +6.11%
2008-09-30 $452.01 Million +8.09%
2007-09-30 $418.18 Million +6.93%
2006-09-30 $391.07 Million +12.01%
2005-09-30 $349.14 Million +9.06%
2004-09-30 $320.14 Million +8.85%
2003-09-30 $294.12 Million +3.58%
2002-09-30 $283.94 Million +4024.07%
2001-09-30 $6.89 Million +65.60%
2000-09-30 $4.16 Million --

Equity Component Analysis

This analysis shows how different components contribute to Ambu A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 521200000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (September 2024)

Component Amount Percentage
Retained Earnings $5.21 Billion 93.17%
Common Stock $135.00 Million 2.41%
Other Comprehensive Income $145.00 Million 2.59%
Other Components $102.00 Million 1.82%
Total Equity $5.59 Billion 100.00%

Ambu A/S Competitors by Market Cap

The table below lists competitors of Ambu A/S ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ambu A/S's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,393,000,000 to 5,594,000,000, a change of 201,000,000 (3.7%).
  • Net income of 235,000,000 contributed positively to equity growth.
  • Other comprehensive income decreased equity by 66,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $235.00 Million +4.2%
Other Comprehensive Income $-66.00 Million -1.18%
Other Changes $32.00 Million +0.57%
Total Change $- 3.73%

Book Value vs Market Value Analysis

This analysis compares Ambu A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.95x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 11.27x to 0.95x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-09-30 $1.77 $19.90 x
2003-09-30 $1.83 $19.90 x
2004-09-30 $1.93 $19.90 x
2005-09-30 $1.48 $19.90 x
2006-09-30 $1.67 $19.90 x
2007-09-30 $1.77 $19.90 x
2008-09-30 $1.92 $19.90 x
2009-09-30 $2.03 $19.90 x
2010-09-30 $2.37 $19.90 x
2011-09-30 $2.44 $19.90 x
2012-09-30 $2.83 $19.90 x
2013-09-30 $2.83 $19.90 x
2014-09-30 $3.52 $19.90 x
2015-09-30 $4.19 $19.90 x
2016-09-30 $4.07 $19.90 x
2017-09-30 $5.26 $19.90 x
2018-09-30 $7.60 $19.90 x
2019-09-30 $8.82 $19.90 x
2020-09-30 $9.57 $19.90 x
2021-09-30 $15.61 $19.90 x
2022-09-30 $16.75 $19.90 x
2023-09-30 $20.69 $19.90 x
2024-09-30 $20.97 $19.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ambu A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.20%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 4.36%
  • • Asset Turnover: 0.75x
  • • Equity Multiplier: 1.28x
  • Recent ROE (4.20%) is below the historical average (10.81%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 0.00% 0.00% 0.00x 1.21x $-415.77K
2001 0.00% 0.00% 0.00x 1.20x $-688.51K
2002 5.28% 2.61% 1.02x 1.98x $-13.41 Million
2003 8.84% 4.59% 1.02x 1.89x $-3.40 Million
2004 10.40% 5.47% 1.03x 1.85x $1.27 Million
2005 10.80% 5.76% 0.99x 1.88x $2.78 Million
2006 12.38% 6.76% 1.06x 1.73x $9.31 Million
2007 10.23% 5.98% 1.05x 1.63x $959.10K
2008 11.06% 6.38% 1.07x 1.62x $4.81 Million
2009 11.63% 6.36% 1.12x 1.63x $7.80 Million
2010 14.97% 8.94% 1.07x 1.56x $27.90 Million
2011 11.94% 7.04% 1.11x 1.53x $11.23 Million
2012 16.22% 10.52% 1.08x 1.42x $42.19 Million
2013 7.20% 3.47% 0.73x 2.84x $-18.70 Million
2014 17.68% 9.53% 0.77x 2.40x $65.60 Million
2015 14.67% 8.05% 0.84x 2.18x $48.40 Million
2016 25.20% 12.00% 0.88x 2.39x $150.80 Million
2017 23.53% 12.78% 0.94x 1.95x $173.10 Million
2018 17.91% 12.93% 0.62x 2.25x $148.80 Million
2019 14.53% 11.24% 0.62x 2.09x $98.80 Million
2020 10.16% 6.76% 0.72x 2.08x $3.80 Million
2021 6.25% 6.15% 0.70x 1.45x $-148.20 Million
2022 2.18% 2.09% 0.62x 1.69x $-333.10 Million
2023 3.12% 3.52% 0.70x 1.27x $-371.30 Million
2024 4.20% 4.36% 0.75x 1.28x $-324.40 Million

Industry Comparison

This section compares Ambu A/S's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $694,749,556
  • Average return on equity (ROE) among peers: -25.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Ambu A/S (AMBFF) $5.91 Billion 0.00% 0.25x $3.41 Billion
Advanced Biomedical Technologies Inc (ABMT) $-4.46 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $191.37 Billion
Acarix AB (publ) (ACIXF) $1.93 Million -127.02% 0.21x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-72.62 Million 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $-12.69K 0.00% 0.00x $3.17 Million
Aethlon Medical Inc (AEMD) $-3.07 Million 0.00% 0.00x $2.79 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $2.07 Billion 7.56% 1.54x $914.25 Million
Allied Healthcare Products Inc. (AHPIQ) $8.88 Million -33.95% 1.22x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $3.39 Million -59.65% 0.38x $9.18 Million